Component
Serotonin-producing neuroendocrine tumor state
Serotonin-producing neuroendocrine tumor state. The model and exposure of each linked claim define its scope.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
In the selected NET cohort, mean plasma tryptophan was 31.8 micromol/L and 45% had urinary N1-methylnicotinamide below the study reference range.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- cross_nutrient
- L-Tryptophan (measured_precursor); N1-methylnicotinamide (measured_metabolite)
- evidence_span
- {"source_cache": "artifacts/niacin-clinical-sources/bouma2016.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497", "start_char": 0, "end_char": 1869, "text_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497"}
- experimental_model
- Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references
- exposure
- Patients selected for low tryptophan and/or pellagra-associated symptoms; prescribed oral niacin mean 144 mg/day
- limitations
- No randomized comparator or direct tracer measurement of tryptophan diversion. Biomarker normalization does not establish symptom cure. Indexed abstract does not unambiguously specify the administered chemical form; retain niacin rather than guessing nicotinamide.
- nutrient_topic
- Niacin research collection; topical membership is not evidence of a direct dietary effect. · Niacin (vitamin B3)
- organism
- Homo sapiens
- plain_language
- In some serotonin-producing tumor patients, low tryptophan was accompanied by a low niacin marker.
- primary_references
- [nia-clin-bouma2016] Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. (2016). https://pubmed.ncbi.nlm.nih.gov/26335390/ DOI: 10.1159/000440621
- tissue_or_cell_type
- Plasma and urine
- trigger_kind
- biomarker_context Imported condition classification; unverified.
Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17) · lines 1263–1275
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references · source_derived_draft · unverified_draft
### nia-clin-net-low-marker In the selected NET cohort, mean plasma tryptophan was 31.8 micromol/L and 45% had urinary N1-methylnicotinamide below the study reference range. Condition category: biomarker_context nutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect. plain_language: In some serotonin-producing tumor patients, low tryptophan was accompanied by a low niacin marker. organism: Homo sapiens tissue_or_cell_type: Plasma and urine experimental_model: Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references limitations: No randomized comparator or direct tracer measurement of tryptophan diversion. Biomarker normalization does not establish symptom cure. Indexed abstract does not unambiguously specify the administered chemical form; retain niacin rather than guessing nicotinamide. exposure: Patients selected for low tryptophan and/or pellagra-associated symptoms; prescribed oral niacin mean 144 mg/day cross_nutrient: L-Tryptophan (measured_precursor); N1-methylnicotinamide (measured_metabolite) evidence_span: {"source_cache": "artifacts/niacin-clinical-sources/bouma2016.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497", "start_char": 0, "end_char": 1869, "text_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497"} [nia-clin-bouma2016] Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. (2016). https://pubmed.ncbi.nlm.nih.gov/26335390/ DOI: 10.1159/000440621
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.